Syvart Dennen, Marty Masek, Paul Cockrum, Ravi Kumar Paluri. "Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.693